Minimal Residual Disease (MRD) ratio before and after Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma

被引：0
|
作者：
Boncompagni, Riccardo [1 ]
Staderini, Michela [2 ]
Nozzoli, Chiara [1 ]
Antonioli, Elisabetta [2 ]
Caporale, Roberto [3 ]
Peruzzi, Benedetta [3 ]
Cutini, Ilaria [1 ]
Gozzini, Antonella [1 ]
Serena, Mariotti [1 ]
Guidi, Stefano [1 ]
Jance, Blerina [3 ]
Accogli, Barbara [2 ]
Francesco, Annunziato [3 ]
Bosi, Alberto [2 ]
Saccardi, Riccardo [1 ]
机构：
[1] AOU Careggi, Cell Therapy & Transfus Med Unit, Florence, Italy
[2] AOU Careggi, Hematol Unit, Florence, Italy
[3] AOU Careggi, Diagnost Ctr Cytometry & Immunotherapy, Florence, Italy
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
autologous stem cell transplant; Minimal residual disease; Progression-free survival;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP-203
引用
收藏
页码：E172 / E172
页数：1
相关论文
共 50 条
  • [31] Melphalan Dose Intensity for Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma
    Srour, Samer A.
    Milton, Denai
    Bashir, Qaiser
    Mehta, Rohtesh S.
    Delgado, Ruby
    Rondon, Gabriela
    Nieto, Yago
    Hosing, Chitra M.
    Popat, Uday R.
    Ciurea, Stefan O.
    Patel, Krina
    Lee, Hans C.
    Manasanch, Elisabet
    Thomas, Sheeba
    Weber, Donna
    Orlowski, Robert Z.
    Champlin, Richard E.
    Qazilbash, Muzaffar H.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [32] Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
    Ruth M. de Tute
    Gordon Cook
    David A. Cairns
    Julia M. Brown
    Jamie Cavenagh
    A. John Ashcroft
    John A. Snowden
    Kwee Yong
    Eleni Tholouli
    Matthew Jenner
    Anna Hockaday
    Mark T. Drayson
    Treen C. M. Morris
    Andy C. Rawstron
    Roger G. Owen
    Bone Marrow Transplantation, 2024, 59 : 431 - 434
  • [33] Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial
    de Tute, Ruth M.
    Cook, Gordon
    Cairns, David A.
    Brown, Julia M.
    Cavenagh, Jamie
    Ashcroft, A. John
    Snowden, John A.
    Yong, Kwee
    Tholouli, Eleni
    Jenner, Matthew
    Hockaday, Anna
    Drayson, Mark T.
    Morris, Treen C. M.
    Rawstron, Andy C.
    Owen, Roger G.
    BONE MARROW TRANSPLANTATION, 2024, 59 (03) : 431 - 434
  • [34] Stem Cell Mobilization Capacity Is Not a Predictor of Survival in Multiple Myeloma (MM) After Autologous Stem Cell Transplantation (ASCT)
    Lim, Gloria
    Xu, Wei
    Young, Trieu
    Winter, Andrew
    Reece, Donna E.
    Trudel, Suzanne
    Kukreti, Vishal
    Anglin, Peter
    Chen, Christine
    BLOOD, 2009, 114 (22) : 847 - 847
  • [35] Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
    Liu, Jiahui
    Yan, Wenqiang
    Fan, Huishou
    Xu, Jingyu
    Li, Lingna
    Du, Chenxing
    Mao, Xuehan
    Yan, Yuting
    Xu, Yan
    Sui, Weiwei
    Deng, Shuhui
    Yi, Shuhua
    Anderson, Kenneth C.
    Qiu, Lugui
    Zou, Dehui
    An, Gang
    CANCER RESEARCH COMMUNICATIONS, 2023, 3 (09): : 1770 - 1780
  • [36] Role of disease status prior autologous stem cell transplantation (ASCT) on survival in patients with multiple myeloma
    Ben Abdeljelil, Nour
    El Fatmi, Rym
    Belloumi, Dorra
    Torjemane, Lamia
    Lakhal, Amel
    Ladeb, Saloua
    Ben Othman, Tarek
    BONE MARROW TRANSPLANTATION, 2018, 53 : 656 - 656
  • [37] MRD NEGATIVITY PROLONGS PFS BUT NOT OS AFTER UPFRONT AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA
    Remes, K.
    Hirviniemi, M.
    Putkonen, M.
    Kairisto, V.
    Juvonen, V.
    Kauppila, M.
    Salmenniemi, U.
    Salmi, T.
    Itala-Remes, M.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S356 - S357
  • [38] Molecular monitoring of minimal residual disease after autologous or allogeneic transplantation for multiple myeloma.
    Corradini, P
    Tarella, C
    Astolfi, M
    Voena, C
    Ladetto, M
    Majolino, I
    Bacigalupo, A
    Boccadoro, M
    Pileri, A
    BLOOD, 1996, 88 (10) : 2464 - 2464
  • [39] Autologous stem cell transplantation (ASCT) followed by consolidation chemotherapy for multiple myeloma (MM).
    Gojo, I
    Murthy, A
    Fassas, A
    Tricot, G
    Fenton, R
    Mookerjee, B
    Meisenberg, B
    Takebe, N
    Frankel, SR
    Sarkodee-Adoo, C
    Heyman, MR
    Ruehle, K
    Smith, R
    Chen, T
    Rapoport, A
    BLOOD, 2000, 96 (11) : 369B - 369B
  • [40] Autologous stem cell transplantation (ASCT) followed by consolidation chemotherapy for multiple myeloma (MM).
    Murthy, A
    Gojo, I
    Fassas, A
    Tricot, G
    Fenton, R
    Mookerjee, B
    Meisenberg, B
    Takebe, N
    Lipani, T
    Badros, A
    Phillips, G
    Sarkodee-Adoo, C
    Heyman, M
    Ruehle, K
    Smith, R
    Guo, CF
    Rapoport, A
    BLOOD, 2001, 98 (11) : 685A - 685A
12345